NCT04260009View on ClinicalTrials.gov

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 1, 2020

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2025

Conditions
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorsSolid Tumors
Interventions
DRUG

Brigatinib

Brigatinib tablets

DRUG

Brigatinib AAF

Brigatinib age-appropriate formulation (AAF)

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04260009 - Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors | Biotech Hunter | Biotech Hunter